Lonza Group AG is a Swiss contract development and manufacturing organization (CDMO) serving the pharmaceutical, biotechnology and nutrition sectors. Headquartered in Basel, it operates a global network with major manufacturing hubs in Visp and Stein, Switzerland. The company supports programs from early development through commercial supply.
Lonza’s capabilities span mammalian and microbial biologics (including monoclonal antibodies and bioconjugates such as antibody–drug conjugates), small‑molecule synthesis including highly potent APIs (HPAPIs), cell and gene therapy manufacturing, and drug product services such as sterile fill‑finish and lyophilization. It also supplies capsules and dosage‑form solutions following the acquisition of Capsugel. Operations are conducted under international cGMP and quality systems. Lonza is listed on the SIX Swiss Exchange (ticker: LONN) and traces its origins to 1897. In 2021, it separated its Specialty Ingredients business (now Arxada) to focus on healthcare manufacturing and services.